Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Scientific advice — is drug repurposing missing a trick?

Scientific Advice meetings are a mechanism to improve communications between drug developers and regulators during the drug-development process. While standard practice for industry, the benefits provided by these meetings are under-utilised by academia. In the context of drug repurposing, can scientific advice, as part of a proposed new R&D tax credits scheme, help to unblock some of the obstacles in the way to clinical adoption?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V. & Sukhatme, V. P. The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience 8, 442 (2014).

    Article  Google Scholar 

  2. Bertolini, F., Sukhatme, V. P. & Bouche, G. Drug repurposing in oncology — patient and health systems opportunities. Nat. Rev. Clin. Oncol. 12, 732–742 (2015).

    Article  Google Scholar 

  3. Davies, E. H., Fulton, E., Brook, D. & Hughes, D. A. Affordable orphan drugs: a role for not-for-profit organizations. Br. J. Clin. Pharmacol. http://dx.doi.org/10.1111/bcp.13240 (2017).

  4. UK Parliament. Off-patent Drugs Bill 2015–2016. Parliament.uk http://services.parliament.uk/bills/2015-16/offpatentdrugs.html (2015).

  5. Hadji, P. et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel. Ann. Oncol. 27, 379–390 (2016).

    Article  CAS  Google Scholar 

  6. Pasquier, E. et al. Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study. EBioMedicine 6, 87–95 (2016).

    Article  Google Scholar 

  7. Chow, W. et al. Growth attenuation of cutaneous angiosarcoma with propranolol-mediated β-blockade. JAMA Dermatol. 151, 1226–1229 (2015).

    Article  Google Scholar 

  8. Regnstrom, J. et al. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur. J. Clin. Pharmacol. 66, 39–48 (2010).

    Article  Google Scholar 

  9. Hofer, M. P. et al. Regulatory watch: impact of scientific advice from the European Medicines Agency. Nat. Rev. Drug Discov. 14, 302–303 (2015).

    Article  CAS  Google Scholar 

  10. Yordanov, Y. et al. Avoidable waste of research related to inadequate methods in clinical trials. BMJ 350, h809 (2015).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pan Pantziarka.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pantziarka, P. Scientific advice — is drug repurposing missing a trick?. Nat Rev Clin Oncol 14, 455–456 (2017). https://doi.org/10.1038/nrclinonc.2017.69

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.69

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer